

2024 ENTERPRISE AWARDS

 PACT





Fairmount Partners is proud to support PACT as Title Sponsor for the 19th consecutive year.

We congratulate the finalists of the 31st Annual Enterprise Awards!

Fairmount Partners is a leading independent investment bank providing M&A, capital raising, and strategic advisory services to middle market and emerging growth companies spanning the Technology, Consulting & Technology Services, Healthcare, and Industrial & Consumer sectors. Over our 20-year history, we have advised clients on over 290 transactions in 23 countries accounting for more than \$17 billion in aggregate value.

fairmountpartners.com

Fairmount Partners is a registered Broker Dealer, member FINRA and SIPC.



Table of Contents

Thank You to Sponsors.....	5
Welcome.....	7
Awards and Honors.....	9-17
Judges	18-19
Tribute Companies	50

AWARDS

Life Sciences & Healthcare Startup.....	21
Technology Startup.....	25
Life Sciences & Healthcare Investment Deal.....	27
Technology Investment Deal	31
Life Sciences & Healthcare Emerging... ..	35
Technology Emerging	39
Life Sciences & Healthcare CEO.....	41
Technology CEO.....	45
Healthcare Innovator	47



Proud supporter of those who reach higher

KPMG is proud to support PACT and their mission to drive entrepreneurship and innovation in the Philadelphia area. KPMG congratulates all nominees and winners for this year's Enterprise Awards.

kpmg.com/us

© 2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. USCS013592-1B

Thank You Sponsors

Title Sponsor:



Judging Partner:




Award Sponsors:



Event Sponsors:





Bernstein Philadelphia is proud to sponsor the

PACT Enterprise Awards

Bernstein Private Wealth Management serves as confidants to some of the world's most astute investors, helping them solve complex challenges—ones that extend well beyond wealth management. With innovative research, sophisticated modeling, and cutting-edge investment solutions, we guide clients and communities to achieve a more meaningful future.

Bernstein Private Wealth Management
1735 Market Street, Suite 3800
Philadelphia, PA 19103
215.430.5600

INVEST WITH INTENTION®
BERNSTEIN.COM

Welcome to the 31st Annual Enterprise Awards!

Welcome to the Annual Enterprise Awards, a celebration of Philadelphia's entrepreneurial spirit and innovation. Tonight, we gather to honor the remarkable achievements of our city's visionaries and trailblazers.




Despite challenges, our life sciences sector continues to shine, driving forward with groundbreaking discoveries and transformative innovations. Philadelphia's resilience, particularly in pre-seed and seed stages, is evident with \$2.4B across 403 deals (as shown in our 2023 Philadelphia Venture Report with Pitchbook), showcasing our city as a hub for early-stage investment and innovation. The surprising knock-on effects of valuation trends further solidify our position as a dynamic and competitive market. Across diverse sectors, our metro area's resilience speaks volumes about our strength and adaptability.

Tonight, as we celebrate our finalists and winners, let us also celebrate our collective spirit of collaboration, determination, and positive change.

I extend my heartfelt gratitude to our Sponsors for their unwavering support. Thank you all for joining us in celebrating Philadelphia's leading companies and becoming ambassadors of their remarkable journeys.

Here's to another year of extraordinary achievements and boundless possibilities.



Dean E. Miller, PACT President & CEO



2024 Enterprise Awards Ceremony

AWARDS

MAY 21, 2024 - 5:30 PM

HOSTED BY

Dean Miller

President & CEO, PACT

and

Stephanie Humphrey

Technology & Lifestyle Contributor,
Merit Street Media &
PACT Board Member

AWARD ORDER

Life Sciences & Healthcare Startup

Technology Startup

Life Sciences &
Healthcare Investment Deal

Technology Investment Deal

Life Sciences & Healthcare Emerging

Technology Emerging

Life Sciences & Healthcare CEO

Technology CEO

Healthcare Innovator



Harmony Biosciences congratulates the
2024 PACT Enterprise Award
nominees on their well-deserved
recognition.

Harmony Biosciences is a rapidly growing CNS-focused company that is dedicated to bringing innovative medicines to patients living with unmet medical needs. Headquartered in Plymouth Meeting, Pennsylvania, our team of experts from a wide variety of disciplines, backgrounds and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for patients, who are the heart of everything we do.

[HarmonyBiosciences.com](https://www.harmonybiosciences.com)



Life Sciences & Healthcare Startup

CRITERIA:

- Company must have been founded, launched meaningful operations, or pivoted to current strategic focus at some point in the period between January 1, 2020, and December 31, 2023.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

KEY CONSIDERATIONS:

- Product innovation including unmet market need and how that is uniquely addressed by your product/service.
- Management team and its record of achieving success.
- Demonstration of success (e.g., significant milestones, raising capital, revenue, etc.).
- R&D investment strategy.
- Strategies to overcome challenges in financing, development, or commercialization.

Technology Startup


A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.

CRITERIA:

- Company should have been founded, launched meaningful operations, or pivoted to current strategic focus at some point in the period between January 1, 2020, and December 31, 2023.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

KEY CONSIDERATIONS:

- Product or service innovation including market need or assessment.
- Potential for significant growth.
- Management team and its record of achieving success.
- A demonstration of success such as significant milestones, raising capital, and revenue.



From seed to IPO, grow without limits

Our financial solutions for early-stage startups, venture-backed and high-growth companies can grow with you at every stage.

[Innovation Economy Banking](#)

J.P.Morgan

© 2024 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC.

Life Sciences & Healthcare Investment Deal

CRITERIA:

- Deal must have been fully executed between November 1, 2022, and October 31, 2023.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees and consultants must be based in the region.
- Events that qualify for this category include: IPO, Capital Raise, Buy-side or Sell-side of a Merger & Acquisition Transaction.

KEY CONSIDERATIONS:

- Realized returns for the investors and management.
- EBITDA margin and revenue growth.
- Strategic considerations of the deal (e.g. commercial strategy, innovation, and contribution to market development).
- Company performance prior to transaction.
- How the sale or purchase impacted the broader industry(s) of the buyer and/or seller.

Technology Investment Deal

CRITERIA:

- Deal must have been fully executed between November 1, 2022, and October 31, 2023.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees and consultants must be based in the region.
- Events that qualify for this category include: IPO, Capital Raise, Buy-side or Sell-side of a Merger & Acquisition Transaction.

KEY CONSIDERATIONS:

- Realized returns for the investors and management.
- EBITDA margin and revenue growth.
- Strategic considerations of the deal (e.g. commercial strategy, innovation, and contribution to market development).
- Company performance prior to transaction.
- How the sale or purchase impacted the broader industry(s) of the buyer and/or seller.



Congratulations to our valued clients iECURE and James Lovett of Myonex

Always Thinking Forward

We're committed to helping entrepreneurs achieve their business goals.

With you every step of the way, we make your challenges our own.

We provide innovative legal solutions to help you seize tomorrow's opportunities.

Solving problems is our top priority.

Elizabeth D. Sigety
215.918.3554
esigety@foxrothschild.com

Terrence M. Kerwin
610.458.6186
tkerwin@foxrothschild.com

California | Colorado | Delaware | District Of Columbia | Florida | Georgia
Illinois | Massachusetts | Minnesota | Missouri | Nevada | New Jersey | New York
North Carolina Oklahoma | Pennsylvania | South Carolina | Texas | Washington

Attorney Advertising

Fox
Rothschild

Life Sciences & Healthcare Emerging

CRITERIA:

- Company must have been in operation beginning on January 1, 2020. The Company should have no more than 8 years of operating results since its founding.
- Must have sales, grants, or licensing fees.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

KEY CONSIDERATIONS:

- Product or service, including proprietary applications or other competitive advantage.
- The impact on the clinical problem this product or innovation is trying to solve (e.g. saving a hospital money on a procedure, making a clinician more productive, etc.).
- Company milestones including strategic decisions made by the management team that led to growth in revenues and/or earnings, corporate collaborations, or license deals (e.g. ability to raise capital, strategy to achieve break even, ability to realize high gross margins, etc.).

Technology Emerging

A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.

CRITERIA:

- Company must have been in operation before January 1, 2020. Revenues must be less than \$50M. If revenues are projected to exceed \$50M in 2023, please complete the Technology Company application.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

KEY CONSIDERATIONS:

- Product or service innovation, including proprietary technology or other advantage.
- Company milestones including strategic decisions made by management that led to growth in revenues and/or earnings.
- Strength of management team including ability to raise capital.
- Demonstration of a sustainable and scalable business model.



Morgan Lewis

We are proud to sponsor the

**LIFE SCIENCES
& HEALTHCARE
CEO AWARD**

and the **2024 PACT Enterprise Awards**

At Morgan Lewis, we understand the unique challenges faced by leaders in the life sciences and healthcare industries and would like to congratulate all of the nominees and award winners for their continued dedication to advancing innovations in healthcare and life sciences in the region.

Our **Emerging Companies & Venture Capital Practice (ECVC)** offers personalized and effective long-term representation tailored to your growth needs from startup to maturity.

Our **Startup & Accelerate** resource center provides analysis and thinking related to your startup and how you can quickly begin moving your venture forward.

www.morganlewis.com

© 2024 Morgan Lewis | Morgan, Lewis & Bockius LLP, a Pennsylvania limited liability partnership. This material is provided for your convenience and does not constitute legal advice or create an attorney-client relationship. Prior results do not guarantee similar outcomes. Attorney Advertising.

Life Sciences & Healthcare CEO

CRITERIA:

- Individual's background and the company's success to date.
- Company must be based in the region and their company must have their HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
- CEO must be in her/his position for at least 2 years.

KEY CONSIDERATIONS:

- CEO's management accomplishments and philosophy, including the communication of a vision and goals as achieved by the company.
- Leadership and impact in industry and/or market.
- Ability to attract and retain talented resources.
- Company milestones including financial accomplishments and a strategy for continued company success.
- Community/industry involvement.
- Extra consideration is given to leaders who have contributed more broadly to the strengthening and promotion of the life sciences/healthcare industry in the region.
- Ability to attract and retain talented resources.

Technology CEO

A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.

CRITERIA:

- Individual's background and the company's success to date.
- CEO must be based in the region and their company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
- CEO must be in her/his position for at least 2 years.

KEY CONSIDERATIONS:

- CEO's management accomplishments and philosophy, including the communication of a vision and goals as achieved by the company.
- Leadership and impact in industry and/or market.
- Ability to attract and retain talented resources.
- Company milestones including financial accomplishments and a strategy for continued company success.
- Community/industry involvement.
- Extra consideration is given to leaders who have contributed more broadly to the strengthening and promotion of the technology industry in the region.



Congratulations to all the PACT Enterprise Awardees & Finalists

The Science Center salutes you for powering progress
that advances innovation and improves lives.

sciencecenter.org



Healthcare Innovator

CRITERIA:

- The nominee can be a company, researcher, or investor providing an innovative solution that has the potential to make a large and positive impact on cost, quality, and/or access in health care.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

KEY CONSIDERATIONS:

- The nominee must demonstrate creativity and passion to re-thinking healthcare in the region and to driving exceptional health outcomes or dramatically lowering costs.
- The nominee should have a demonstrated business model for its solution and demonstrate the ability to generate rapid growth or adoption.
- The nominee should be able to demonstrate return on investment or clinical impact of its solution.
- The nominee can be in any sector (technology, life sciences, investment, health care delivery, etc.), but must be serving the healthcare industry in Greater Philadelphia.



Lead Judge

Rick Riegel

Chairman, ActiGraph and Deerfield

Technology Judging Panel Oversight



Andrew Cherry

Partner, KPMG

TECHNOLOGY JUDGES

Suchit Bachalli

Chief Executive Officer

Unilog

Bharat Santhanam

Principal

NewSpring Capital

Mike Bachman

Global Architect & Principal Technologist

Boomi

Sneha Shah

EVP New Business Ventures

SEI

Sean Dowling

Partner

Osage Partners

Kweli Washington

Chief People Officer

Piano Software

Alex King

Co-Managing Partner

Plain Sight Capital

Mark Weinstein

Chairman of Board of Directors

Strategikon Pharma

Rick Nucci

Chief Executive Officer

Guru

Life Sciences & Healthcare Judging Panel Oversight



Tom Koncsics
Partner, KPMG



Jennifer Strong
Partner, KPMG

LIFE SCIENCES & HEALTHCARE JUDGES

Tom Anderson

Former CEO
SwanBio

Carol Burns

Co-Founder, President & CEO
Cagent Vascular

Mike DeFeo Jr.

Vice President, Life Sciences Commercial Banking
J.P. Morgan Chase

Gerianne (Gerie) DiPiano

Chairman & CEO
FemmePharma

Tiara Durham

Director of New Ventures
University City Science Center

Audrey Greenberg

Co-Founder & Chief Business Officer
Center for Breakthrough Medicines,
now SK pharmteco

Eric Heil

Managing Partner
Medical Excellence Capital

Jackie Hollenbach

Vice President, Research and Development
Teleflex

Joan Lau

Chief Executive Officer
Spirovant Sciences

Matthew Reber


Partner
1315 Capital

Congratulations to all of the Enterprise Award Finalists!

Blank Rome is proud to support PACT and all of its members in their continued dedication and commitment to innovation, growth, and the community.

BLANKROME
blankrome.com

Delivering Value to Emerging Companies



Code Biotherapeutics

Code Bio's non-viral approach to genetic medicine delivery provides the potential to be a next generation product offering following the AAV-based gene therapy and siRNA-based therapeutics that are being marketed and/or approved today. As a DNA-based, non-viral vector, a 3DNA-based genetic medicine may potentially be dosed even if someone has already received another gene therapy. The breadth of utility of the 3DNA platform means it can potentially be used to treat both rare and prevalent genetic diseases. Code Bio has assembled a diverse team and has generated data to advance it's initial pipeline program in Duchenne Muscular Dystrophy (DMD) into preclinical development.



iECURE

iECURE is a clinical-stage biotech company focused on developing therapies that utilize mutation-agnostic in vivo gene editing for the treatment of liver disorders with significant unmet need. Their approach has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation, by knocking-in a healthy copy of that gene to offer durable gene expression and long-term, potentially curative, therapeutic benefit. iECURE's lead candidate ECUR-506 is an investigational gene editing therapy designed to address the underlying genetic cause of Ornithine Transcarbamylase (OTC) deficiency. ECUR-506 represents the first in vivo gene insertion program authorized for clinical investigation in male infants in the U.S.



Trialbee

Trialbee has emerged as a global leader in utilizing technology to help biopharma companies solve the number one challenge in clinical development – enrolling patients into their clinical trials. In 2020 the company established new leadership and refocused the company's strategy on technology. In the past three years the business achieved a revenue CAGR of 100% while tripling the employee base. Today Trialbee' global platform enrolls patients into clinical trials across dozens of countries for 8 of the top 10 global pharmaceutical companies.



Sponsor:

BLANKROME

Mineralys Therapeutics, Inc. was founded in 2020 with the licensing of MLS-101 (lorundrostat) from Mitsubishi Tanabe Pharma Company. Mineralys has raised approximately \$500M gross proceeds through Series A, Series B, IPO and PIPE financings to further the development of lorundrostat. Lorundrostat is a selective aldosterone synthase inhibitor that is being developed to target masked hyperaldosteronism in cardiorenal metabolic diseases. In a phase 2, dose-range findings, proof-of-concept study, lorundrostat delivered double-digit placebo-adjusted reduction in systolic blood pressure while demonstrating a safe and well-tolerated profile. Lorundrostat is currently in three pivotal studies for hypertension and one PoC for hypertension and CKD.





Congratulations to the **PACT** **2024 Enterprise** **Award** Finalists!

Thank you for leading our region's significant contributions to technology, life sciences, and healthcare.

Adaptimmune is working to redefine the treatment of solid tumor cancers with personalized medicines. We use cell therapies to tackle difficult-to-treat solid tumor cancers by engineering a person's own T-cell to fight their cancer. We're a fully integrated cell therapy company with four locations in biotechnology hubs in the U.S. and U.K., including U.S. headquarters in Philadelphia.

Arming cells. Against cancer. For good.



www.adaptimmune.com

Supporting visionaries.

We proudly support **PACT** and greater Philadelphia's vibrant community of entrepreneurs. Congratulations to the **2024 Enterprise Award** honorees.

troutman pepper
seed

troutman.com

Troutman Pepper Hamilton Sanders LLP



troutman
pepper

Carenostics

Carenostics, a pioneering healthcare AI startup, revolutionizes chronic disease management by leveraging electronic health records to identify undiagnosed and undertreated patients. Specifically, Carenostics partners with health systems to proactively identify high-risk chronic disease patients and enable earlier clinical intervention to avoid preventable complications, hospitalizations, and deaths. Carenostics' award-winning PREDICT platform is adaptable across diseases to significantly increase diagnoses, identifying 3X more Chronic Kidney Disease patients and 20X Severe Uncontrolled Asthma patients compared to standard practices. By integrating these insights back into clinical workflows and driving industry-leading clinical adoption rates, Carenostics drives increased preventative intervention to radically improve patient outcomes.



Mural Health

Mural Health was founded in 2022 to make clinical trial participation easier. Mural Link, a first-of-its-kind participant management platform, was designed by co-founder and CEO, Sam Whitaker, inventor of ClinCard, the industry's first participant payment technology product in 2008. Mural Link represents a disruption of this original platform, expanding its functionality to meet the needs of modern-day participants. Mural Link's initial features include next-gen payment processing, transportation, two-way messaging, and participant feedback. Mural Link helps participants overcome enrollment and retention barriers, improves site operations, and delivers greater strategic value to sponsors. In 2023, Mural Health raised \$8M in seed funding.



Red Vector

Red Vector offers an innovative software platform, FULCRUM®, to empower organizations in monitoring and managing organizational risk. Red Vector equips enterprises with actionable visibility into insider threat, which is critical to uncovering previously unidentified risks and prompting early detection and resolution.



Sponsor:





Congratulations

Bank of America would like to congratulate all of the 2024 Enterprise Award nominees and winners. We applaud you for being recognized with one of the region's most prestigious business honors for technology and life sciences companies, leaders, and entrepreneurs. Thank you for your continued dedication.

bankofamerica.com/about

©2023 Bank of America Corporation | ENT-217-AD

BANK OF AMERICA 

Life Sciences & Healthcare Investment Deal

Harmony Biosciences

Harmony is a commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people with rare neurological disorders. As part of its growth strategy, Harmony acquired Zynerva, whose asset is a 'portfolio in a product' and the first-and-only pharmaceutically manufactured synthetic, non-euphoric cannabidiol formulated as a patent-protected permeation-enhanced gel for delivery through skin. Harmony paid approximately \$60M in cash upon the closing of the transaction and received approximately \$26M in cash and \$45M in deferred tax assets from the acquisition. Harmony acquired 2 late-stage programs that have an international intellectual property portfolio including seven U.S. patents and one EU patent related to methods of treating Fragile X syndrome, 22q11.2 deletion syndrome and autism spectrum disorder.



Mineralys

Mineralys Therapeutics was founded in 2020 with the licensing of MLS-101 (lorundrostat) from Mitsubishi Tanabe Pharma. Mineralys has raised \$500M gross proceeds through Series A, B, IPO and PIPE financings to further the development of lorundrostat. Lorundrostat is a selective aldosterone synthase inhibitor that is being developed to target masked hyperaldosteronism in cardiorenal metabolic diseases. In a phase 2, dose-range findings, proof-of-concept study, lorundrostat delivered double-digit placebo-adjusted reduction in systolic blood pressure while demonstrating a safe and well-tolerated profile. Lorundrostat is currently in three pivotal studies for hypertension, PoC for hypertension and CKD.



SK pharmteco

In October 2023, SK pharmteco acquired a majority stake in the Center for Breakthrough Medicines. This transformative deal, backed by SK Group's \$22B commitment to the US, saw CBM become a global powerhouse overnight as part of SK pharmteco's 2,000 employees, delivering treatments to 70,000 patients annually. The collaboration enhances CBM's advanced therapy capabilities, positioning us as the preeminent Cell and Gene Therapy CDMO in the world.



Sponsor:





**AscellaHealth is proud to be
Recognized as a 2024 PACT
Enterprise Award**



**Healthcare
Innovator Finalist**

Congratulations to all other finalists!


A Global Specialty Pharmacy & Healthcare Services Provider

Serving Patients, Life Sciences Manufacturers, Payers and Providers

- Pre-Commercialization & Market Access
- Specialty Pharmacy Fulfillment
- Distribution, Wholesale, 3PL Services
- Patient Support & HUB Services
- Pharmaceutical Financial Solutions for High-Cost Therapies
- Customizable Copay Assistance Programs
- Specialty Pharmacy & Medical Benefit Management

ascellahealth.com

PHAD032402.07



Turning the complexity of a solid tumor against itself

Personalized, whole tumor-derived immunotherapies


Imvax is honored to be nominated for LIFE SCIENCES AND HEALTHCARE EMERGING

and extends its congratulations to
the other category nominees:
Adaptimmune and BioAnalysis

Imvax is a Philadelphia-based clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors.



www.imvax.com



Is it possible
to drive my
business
forward—
securely?

Comcast Business
is honored to be
a sponsor of **2024
Enterprise Awards**.
Congratulations to
this year's honorees.

It's not just possible. It's happening with global secure networking from Comcast Business. If your business is pushing for more, choose the network that can keep up.

ComcastBusiness.com

©2023 Comcast. All rights reserved.

COMCAST
BUSINESS

Technology Investment Deal

Qlik

Qlik, with the recent acquisition of Talend, delivers an industry-leading portfolio of solutions for data integration, data quality, and analytics. This includes advancements in real-time AI, ML, and automation. Qlik's acquisition of Talend tied together two data analytics and visualization vendors backed by Thoma Bravo, and has allowed customers and partners greater access to complementary products supporting the entire lifecycle of data and analytic needs. Together, their complementary solutions extend the capabilities of many vital areas such as data quality, transformation, application connectivity, and API services.



Tendo

Tendo creates seamless care experiences, connecting patients, clinicians, and caregivers with intuitive, intelligent software and analytics. We envision a healthier, connected world without the frustration that results from the current fragmented healthcare landscape. We acquired MDsave, the largest US healthcare network, featuring 350+ hospitals and 5000+ care sites, with 15 patents for innovative bundled and virtual care. With this integration, we now can offer unparalleled transparency, allowing patients to access, schedule, and engage in care with ease. This acquisition drives digital transformation, providing the most comprehensive solution for patients' healthcare needs, bridging the gap in today's complex healthcare ecosystem.



Transcend

Transcend Software, the leading SaaS provider of generative design tools for critical infrastructure, announced the close of a \$20M Series B financing round in 2023. Participants included Autodesk, a leading software provider for the architecture, engineering, construction, manufacturing, product design, and media industries. Existing investors HG Ventures, PureTerra and Aspen Capital Group also participated, along with new investors Arosa Capital and Riverstone Holdings. Autodesk's commitment is a clear indicator that the world is moving towards the automation of preliminary design activities to develop resilient infrastructure for the future.



Sponsors:




withum⁺
ADVISORY TAX AUDIT

navigating the future

Withum's Technology and Emerging Growth Services Practice is Proud to Support PACT's 2024 Enterprise Awards!

withum.com/tech



We salute Karla Trotman
on being named a PACT
2024 Enterprise Award Finalist
for Technology CEO



Electronics Contract Manufacturing Services

It's always a pleasure
to recognize the
achievements of our clients
and friends of the firm.

RSM is proud to support PACT and the
2024 Enterprise Awards.

rsmus.com

THE POWER OF BEING UNDERSTOOD
ASSURANCE | TAX | CONSULTING



RSM US LLP is the U.S. member firm of RSM International, a global network of independent assurance, tax and consulting firms. Visit rsmus.com/aboutus for more information regarding RSM US LLP and RSM International.

Life Sciences & Healthcare Emerging

Adaptimmune

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer. We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the first engineered T-cell therapy in solid tumors to help improve cancer treatment.



BioAnalysis

BioAnalysis, LLC is a small, agile CRO. Our scientists will collaborate with your team to build productive and effective solutions. The traditional CRO model works well, but at BioAnalysis, LLC we believe that collaborative interactions, open communication, and robust experimental design are the gold-standard way to produce valuable results. Our solutions are carefully designed to support your unique product. With our team of subject matter experts, BioAnalysis is focused on providing the most comprehensive and scientifically robust analysis available. Our experience ensures the highest standards of scientific rigor are applied to every project while our thorough investigation ensures complete results without unnecessary experiments.



Imvax

Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax's most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax's portfolio also includes several other programs designed to stimulate a patient's immune system against the entire antigen signature of their tumor. Imvax is headquartered in Philadelphia, Pennsylvania.



Sponsor:



DUANE MORRIS
IS PLEASED TO
SPONSOR THE
PACT 2024
ENTERPRISE
AWARDS

Duane Morris LLP is a law firm with more than 900 attorneys in offices across the United States and internationally. We work with entrepreneurs and investors throughout all stages of the business life-cycle to implement creative and practical strategies to accomplish their business objectives.

Richard L. Cohen

Co-Chair, Emerging Companies/Venture Capital

215.979.1233 | rlcohen@duanemorris.com

Rebecca A. Guzman

302.657.4928 | raguzman@duanemorris.com

Michael S. Harrington

Co-Chair, Emerging Companies/Venture Capital

215.979.1260 | msharrington@duanemorris.com

Elizabeth G. Hodgson

215.979.1262 | ehodgson@duanemorris.com

Duane Morris - Firm and Affiliate Offices | New York | London | Singapore | Philadelphia | Chicago | Washington, D.C. | San Francisco | Silicon Valley
San Diego | Los Angeles | Boston | Houston | Dallas | Fort Worth | Austin | Hanoi | Ho Chi Minh City | Shanghai | Atlanta | Baltimore | Wilmington
Miami | Boca Raton | Pittsburgh | Newark | Las Vegas | Cherry Hill | Lake Tahoe | Myanmar | Duane Morris LLP - A Delaware limited liability partnership



We see your vision

Our KPMG Private Enterprise advisers work with rapidly expanding companies at every stage of the business journey to identify signals of change, explore possibilities, identify opportunities, and develop strategic responses designed with an enterprise-wide perspective.

[visit.kpmg.us/PrivateEnterprise](https://www.kpmg.us/PrivateEnterprise)



Ryan Breen
rbreen@kpmg.com

Andy Cherry
acherry@kpmg.com

Tom Koncsics
tkoncsics@kpmg.com

John Sasselli
jsasselli@kpmg.com

Jen Strong
jstrong@kpmg.com

© 2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. USCS013592-1A

Navigating the Brave New World of AI.

Broadpath is proud to support PACT and the 2024 Enterprise Awards. Congratulations to all of the finalists and honorees.

Broadpath helps technology companies lead their industry dialogue. We are experts at crafting leading-edge content, capturing credible earned media, and optimizing generative AI results.

info@broadpathpr.com
[Broadpathpr.com](https://broadpathpr.com)

Broadpath

Burro

Burro, headquartered in Philadelphia, is a robotics company focused on ridding the world of tedious work outdoors through the use of collaborative robots. Burro's main products, Burro, BurroXL, and Burro Grande, amplify the workforce by carrying, towing, scouting, and patrolling. Today, there are over 350 Burros in paid commercial use with customers, operating on 6 continents, having worked over 75,000 autonomous miles. Burro closed a \$24M Series B in December 2023, which will be used to invest in building out its go to market and product teams.



Cesium

Cesium provides an open software platform for creating 3D geospatial applications on the web or in popular game engines such as Unreal Engine and Unity. With Cesium's technology, developers in industries such as Architecture, Engineering & Construction (AEC), Aerospace & Defense, and Smart Cities stream massive amounts of real-world data to create virtual worlds for visualization, analysis, and simulation. Cesium has grown quickly, moving into large headquarters in Old City Philadelphia, which they open up for community events such as Philly JS Meetups, hackathons, and Black Tech Philly Weekend Workshops. Cesium is enthusiastically dedicated to building the Philadelphia tech community.



DrayNow

DrayNow is revolutionizing intermodal's first and last mile to create unexpected opportunities and exceptional value. Our goal is to make intermodal - the most environmentally sustainable mode of domestic freight transportation - more efficient, more cost-effective, and ultimately the predominant mode for moving domestic freight. DrayNow's platform connects small fleet owner operators with brokers, IMCs, & BCOs who need first and last mile drayage service. Our technology eliminates paperwork, provides real-time geo-tracking & ETAs, and integrates directly with TMS software via EDI & API - all while extending their operational capacity on demand to provide unparalleled transparency and efficiency.



Sponsors:





Top performers. Enormous accolades.

EY is proud to support PACT and celebrate the 2024 Enterprise Award honorees. There's no limit to what we can accomplish when we strive to build a better world together.



**Building a better
working world**

© 2024 Ernst & Young LLP. All Rights Reserved. ED None

Life Sciences & Healthcare CEO

Donna Dorozinsky, *Just In Time GCP*

Founder & CEO of Just in Time GCP, Donna Dorozinsky is a visionary leader and entrepreneur who has over 30 years of experience in drug development and clinical compliance. She is deeply passionate about the business and has the ability to think strategically while paying attention to operational details. She is committed to developing her employees and establishing a strong culture that has built the business to what it is today. Under Donna's leadership, Just in Time GCP has been named to the INC5000 for the past 3 years and was most recently named an INC500 Best Workplaces.



Hervé Hoppenot, *Incyte*

For over 30 years, Hervé Hoppenot has been at the helm of scientific innovation, making a tremendous impact on the biopharma industry through his unwavering dedication to advancing science that may solve challenges for patients with critical unmet medical needs. Since becoming CEO of Incyte in 2014, Hervé has catapulted Incyte forward, further enhancing the company's reputation as a scientific powerhouse. Hervé's leadership has yielded significant advancements for patients, as well as robust business growth for Incyte and expanding operations across North America, Europe and Asia.



James Lovett, *Myonex*

In the five years with James Lovett as CEO, Myonex has delivered 35% compound growth in earnings per year and tripled employment to 220+. Myonex has developed three new services in its mission to improve how clinical trials are supplied, expanding in the US and UK, and completing an acquisition in Germany. James believes that a strong people orientation, focus on results and accountability, and a genuine commitment to integrity are mutually re-enforcing rather than in conflict. Great people want to win and to work in a company where they feel good about their contributions to society, and clients support this kind of company with great people.



Sponsors:



Morgan Lewis



OSAGE
VENTURE PARTNERS

*Early-Stage Venture Firm
Business-to-Business Software With a Focus on
AI-Enabled Future of Work*

***Congratulations to DrayNow
and all other Finalists!***

Funding the Next Wave of Human Achievement

osageventurepartners.com



Congratulations to all the
2024 Enterprise Award
nominees on their well-
deserved recognition.

New Ideas.

New Growth.



NewSpring partners with the innovators, makers, and operators of high-performing companies in dynamic industries to catalyze new growth and seize compelling opportunities. We manage approximately \$3.5 billion across five distinct strategies covering the spectrum from growth equity and control buyouts to mezzanine debt.

When we invest, we bring a wealth of knowledge, experience and resources to take growing companies to the next level and beyond.

www.newspringcapital.com



**WE APPLAUD THE WORK OF OUR CLIENTS,
INCLUDING THOSE WHO ARE AMONG THIS
YEAR'S ENTERPRISE AWARDS FINALISTS.**



Our COpilot program provides a range of resources and services tailored to the needs of early-stage companies. We help entrepreneurs overcome the challenges of starting a new business and realize their full potential.

Proud sponsor of the 2024 Technology CEO of the Year Award

Christopher McDemus
Co-Chair, Emerging Business & Venture Capital
(215) 665-2156 | cmcdemus@cozen.com

Michael Crossey
Co-Chair, Emerging Business & Venture Capital
(215) 665-2195 | mcrossey@cozen.com

825 attorneys | 32 offices | cozen.com


Suchit Bachalli, *Unilog*

Unilog is the leader in connected product content and commerce solutions for distributors, manufacturers, and specialty retailers. As Unilog's CEO, Suchit Bachalli oversees the global sales and solution consulting teams and drives Unilog's business and sales strategies across their product portfolio. He has helped build an ecosystem of customers and partners who attest to the high-quality solutions Unilog delivers. Bachalli's strong industry knowledge and forward-thinking leadership has been an integral part of Unilog's success and was instrumental to securing significant growth capital in 2021 to help him accomplish his vision for the company.




Brian Dainis, *Curotec*

Curotec is a software development firm led by CEO Brian Dainis. Brian's strategy for growing the company includes fostering strong industry partnerships, building effective go-to-market channels, and keeping the company's core offerings focused and relevant. Above all, building and nurturing a team culture where top-tier technologists can thrive is a core focus for Brian.



Karla Trotman, *Electro Soft*

Karla Trotman is the Gen2 owner of Electro Soft. Recognizing the growth potential of her family business, she changed the business model. Armed with a background in supply chain logistics and e-commerce, she leveraged the business strong knowledge and technical foundation to revitalize an otherwise flat revenue streak, attaining 20%+ year-over-year growth. She brought to the forefront the need for strong and knowledgeable manufacturing partners to bring highly technical ideas from paper to fruition yet are oftentimes forgotten as they silently operate in the background. Her passion for revitalizing manufacturing has led to the creation of partnerships and pipelines of tomorrow's manufacturing leaders.



Sponsor:





WE SALUTE

The 2024 Enterprise Award winners

Independence Blue Cross (IBX) is proud to support PACT's **2024 Enterprise Awards**. We recognize the winners for their innovation in technology, life sciences, and investment in the Greater Philadelphia region.

IBX remains steadfast in its support of individuals and community organizations dedicated to improving the lives and health of the people in our region.

Independence 

IBX

AscellaHealth

AscellaHealth is a global healthcare and specialty pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers. AscellaHealth stands out as a leader in the intricate, competitive specialty pharmaceutical ecosystem, driven by its unique, patient-centric and collaborative approach that differentiates the Company from other players. AscellaHealth's uniquely-tailored specialty pharmaceutical services and programs address unmet needs of industry stakeholders and are designed to meet the specific requirements of highly specialized patient populations and complex, chronic disease categories. As a healthcare innovator, AscellaHealth leads the industry with a patient-centric model and tailored solutions for optimizing program and patient outcomes.



Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of novel engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. CABA-201, our investigational CD19-CAR T cell therapy, is currently advancing in Phase 1/2 clinical trials for lupus, myositis, systemic sclerosis and generalized myasthenia gravis, which collectively affect over 500,000 U.S. patients. We believe CABA-201 may address significant unmet need across a broad range of autoimmune diseases with the potential to provide an 'immune reset,' enabling patients to achieve durable disease remission.



Carisma Therapeutics

Carisma Therapeutics is a clinical stage biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages to transform the treatment of cancer and other serious illness.



Sponsor:





Industry Leading Financial Software

- Affordable, secure financial reporting software from the leading SEC filing agent
- VDRs & corporate repositories optimized for productivity
- AI-powered contract analytics that save time and money

Proud to support innovators and leaders
in Life Science and Technology

Michael Annunziata

michael.annunziata@dfinsolutions.com
646.246.9925
www.dfinsolutions.com

Hari Chenglath

hari.chenglath@dfinsolutions.com
917.208.7546
www.dfinsolutions.com





Congratulations to the 2024 PACT Enterprise Award nominees!

Proud PACT supporter since 2017

At Boomi, we understand the power of data in driving successful digital transformation. Our cloud-based integration platform simplifies connectivity across your entire business ecosystem – applications, data, processes, and people. It's designed for speed, ease-of-use, and cost-effectiveness.

Think of Boomi as your strategic integration partner. We help you unify your data and applications, creating a seamless flow that unlocks better, faster results.

Join over 20,000 companies who leverage Boomi as a key driver of their success. Let Boomi empower your business to achieve its full potential.

www.boomi.com

boomi

Tribute Companies

AB Bernstein	6
Adaptimmune	23
AscellaHealth	28
Bank of America	26
Blank Rome	20
Boomi	49
Broadpath	38
Comcast Business	30
Cozen O'Connor	44
DFIN	48
Duane Morris	36
Electro Soft	33
EY	48
Fairmount Partners	2
Fox Rothschild	12
Harmony Biosciences	8
Invax	29
Independence Blue Cross	46
J.P. Morgan	10
KPMG	2, 37
Mineralys	22
Morgan Lewis	14
NewSpring Capital	43
Osage Venture Partners	42
RSM	34
Troutman Pepper	24
University City Science Center	16
Withum Smith + Brown	32





PhiladelphiaPACT.com

Printing Compliments of Donnelley Financial Solutions